These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1094 related articles for article (PubMed ID: 33391507)
1. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507 [TBL] [Abstract][Full Text] [Related]
2. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
3. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells. Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268 [TBL] [Abstract][Full Text] [Related]
4. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance. Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462 [TBL] [Abstract][Full Text] [Related]
5. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer. Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735 [TBL] [Abstract][Full Text] [Related]
6. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757 [TBL] [Abstract][Full Text] [Related]
8. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition. Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611 [TBL] [Abstract][Full Text] [Related]
10. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520 [TBL] [Abstract][Full Text] [Related]
11. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587 [TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice. Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579 [TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326 [TBL] [Abstract][Full Text] [Related]
14. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3. Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284 [TBL] [Abstract][Full Text] [Related]
15. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC. Song X; Wang L; Tang W; Yuan L; Liu Q; Li J; Fan D Arch Pharm Res; 2023 Dec; 46(11-12):924-938. PubMed ID: 38032449 [TBL] [Abstract][Full Text] [Related]
16. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Xie M; He CS; Wei SH; Zhang L Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913 [TBL] [Abstract][Full Text] [Related]
17. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway. Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025 [TBL] [Abstract][Full Text] [Related]
18. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. Fu Y; Zhang Y; Lei Z; Liu T; Cai T; Wang A; Du W; Zeng Y; Zhu J; Liu Z; Huang JA J Hematol Oncol; 2020 Dec; 13(1):169. PubMed ID: 33287873 [TBL] [Abstract][Full Text] [Related]
19. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897 [TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer. Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]